The reiteration of the 'Sector Perform' rating and maintenance of the $26 price target by RBC Capital suggests a neutral outlook on Sage Therapeutics. This indicates that the analyst believes the stock is fairly valued at its current level, implying no significant short-term price movement is expected based on this analysis alone.